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Rafal T MarszalekIt was one Saturday morning in April when, after a 24-hour
journey across half of the world, and a very early morning
start to the 2014 AACR annual meeting marathon, I was
sitting in a dark room in the San Diego Convention Center
listening to Kornelia Polyak’s talk about the evolution of
breast cancer. Polyak, an expert in breast cancer genom-
ics, was reporting on some recent results from her group.
Then, she made a statement that for many cancer re-
searchers will perhaps seem obvious, but that was not yet
obvious to me. Polyak noted that it is not uncommon that
when several different clones of cancer are present in a pa-
tient, the clone that metastasizes is not the most aggres-
sive one.
This does of course make a lot of sense: the clone that
metastasizes doesn’t need to be aggressive at all. Rather,
it needs to be resistant to therapy. And so it is quite logical
that even if other, often more dominant and larger clones
are destroyed by the treatment, the ones that were until
then suppressed suddenly gain breathing space to grow
and migrate. The idea resonated with me a lot, as it
seemed to cover so many concepts and threads that we
were already seeing in the submissions for the special
issue: cancer heterogeneity, clonal diversity, therapy re-
sponse and resistance, and progression of the disease. In
one sentence Polyak unknowingly summarized the issue
of Genome Biology that we now bring you.The cancer genomics explosion
When The Cancer Genome Atlas consortium kicked off
nearly 10 years ago, the initial goal was technically chal-
lenging, but from today’s perspective seems rather mod-
est: to characterize three types of human cancer. Five
years ago it expanded into the next phase, which would
focus on the analysis of around 20 more tumor types. By
now the consortium has sequenced and analyzed the
data from over 10,000 samples, characterizing over 30
tumor types [1].
Another consortium, the International Cancer Genomics
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months following its publication. After this time
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sequencing of over 25,000 samples. The work of both con-
sortia led to a deluge of many types of ‘omic’ data being
available to researchers all over the world, as well as to a
series of high profile publications describing mutational
landscapes in major cancer types.
These consortia did a tremendous job in providing the
community with an incredible resource, but what is be-
coming increasingly clear, is that these analyses represent
an average image of a given cancer: a moment frozen in
time, which often doesn’t reflect the immense heterogen-
eity of the tumors between patients, nor the diversity seen
within patients, nor the changes commonly observed as
the cancer evolves and progresses. To address these issues,
the next phase in cancer genomics research must involve
expansion in a number of new directions.
First, we need to study cancer at different genomic levels,
and analyse the data in an integrative way that can produce
synergistic results (this, to a large extent, is already hap-
pening within the consortia frameworks). That, hopefully,
will give us a better understanding of the cancer hetero-
geneity underlying, for instance, differences in therapy re-
sponse. Second, we should look at cancers at different time
points during their development: to get a better view of
the mechanisms that lead to cancer progression; to better
comprehend what happens when a selective pressure, in
the form of therapy, is applied to the tumor; and to find
new ways of fighting cancers that became resistant to treat-
ment. Finally, we should take a closer look at individual pa-
tients. We should study their primary tumors alongside
the metastatic lesions; and we should study their tumors in
greater depth, to get a better view of rare events in their
genomes that, while not necessarily easy to find, may just
be the ones responsible for the disease outcome.Less is more
Looking in detail at individual patients to get a better
picture of their personal ‘mutational (and other) landscapes’,
trying to identify and characterise rare disease subtypes,
working with samples for which no appropriate reference
is available – all these themes underlying the articles of
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emphasis in cancer genomics is more and more on indi-
viduals [2].
This month we publish two elegant examples of N-of-1
studies, which demonstrate the power of thorough ana-
lysis of one individual. Hanlee Ji and colleagues in one
of these studies [3], and Charles Swanton and colleagues
in the other [4], study single cancer patients with her-
editary gastric cancer and kidney cancer, respectively,
and provide insights into the evolution of these cancer
types. While Ji and colleagues show how such studies
can be additionally informed by a clever choice of models
for mechanistic studies, Swanton and colleagues focus on
demonstrating how cancer development follows basic evo-
lutionary principles.
A wonderful addition on this topic is an Opinion from
Obi Griffith, Andrew Su and colleagues [5] who discuss
a non-trivial issue of how to interpret the data from these
N-of-1 studies, of which we are bound to see more and
more. In their article they raise an interesting issue of per-
sonal investment: while that of the patient is obvious, we
have to realize that personal investment of the researcher
is also needed for us to be able to make the most of the
data that we are so keen to produce, but which is getting
increasingly harder to navigate and interpret.
More is more
The rise of N-of-1 studies does not mean that large co-
hort sequencing is dead. What we already see is the
expansion of projects dedicated to characterization of
different cancer types. Now that several major, common
cancer types have been analyzed, the aim will be to im-
prove the picture that we have of them, for example to
get a clearer view of how their subtypes differ. Our un-
derstanding of this basic heterogeneity is far from good,
and this becomes clear when we realize how unrefined
are common classifications of some of the most frequent
cancer types, as demonstrated by Carlos Caldas, Samuel
Aparicio and colleagues on the example of breast cancer
[6,7]. For other cancers, our view of the different sub-
types that exist is not even yet complete – Colin Collins
and colleagues show, through the transcriptomic analysis
of prostate cancer, that new, rare, and dangerous sub-
types can still be identified [8].
We also have a lot to learn from the analysis of other
data for cancers that are seemingly well-characterized.
In the study from Christopher Maher and colleagues [9],
a search through lung cancer transcriptomes reveals thou-
sands of novel long intergenic non-coding RNAs, which
are dysregulated in this cancer and affect its growth.
Two other studies turn from gene expression to focus
more on DNA methylation: a breast cancer study from
Vessela Kristensen and colleagues [10] and a Wilms
tumor study from Katherine Pritchard-Jones, StephanBeck and colleagues [11] both reinforce the concept that
aberrant methylation may give rise to new biomarkers
of cancer progression. The idea of how this variety and
abundance of data can be better used is further explored
in an Opinion on integrative analyses by Anne-Lise
Børresen-Dale and colleagues [12].
Give me a lever, give me a tool
We may be keen to jump on the problem of cancer het-
erogeneity at once. With sequencing getting ever cheaper
[13] and new technologies waiting for us around every
corner [14], it may seem that addressing this challenge has
never been easier. But we would be nowhere without the
right analytical tools – and the wave of methods for the
analysis of cancer evolution and phylogenies published re-
cently [15-17] only goes to show that the need for a new
toolkit is huge.
Therefore it should be no surprise that in this special
issue we found a place for several excellent Method articles:
Gabor Marth and colleagues describe SubcloneSeeker
(the clue is in the name!) [18] and Francesca Demichelis
and colleagues give us CLONET [19], both of which are
designed for the analysis of clonality. Shirley Liu and
colleagues [20] describe a tool for the identification of
differential methylation in single tumor samples. Interest-
ing and innovative approaches to cancer evolution studies
are also presented in the Research articles from Olivier
Elemento and colleagues [21] who look at lymphoma
development through the prism of VDJ-region sequen-
cing, and from Francesca Ciccarelli and colleagues [22]
who study colorectal cancer by the means of X chromo-
some sequencing.
Another engaging read is an Opinion article on
competition-based evaluation of bioinformatic tools
[23], in which Gustavo Stolovitzky, Andrea Califano and
colleagues discuss the benefits, and the pitfalls of these
community efforts, which are being more and more often
used to find the most suitable and imaginative tools to
deal with complex bioinformatic problems.
Without further ado
And so, without further ado, we invite you to browse
through these, and other, articles included in this special
collection on the genomics of cancer progression and
heterogeneity [24]. While we realize that with this issue
we barely scratched the surface of this area of research,
every day we are reminded with new studies being pub-
lished how much is being done and learned, and how
much to do and to learn there still is.
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